Key Quantitative Figures - Standalone (Rs. in Lakhs)

Quarterly Performance (Q2 FY27)

  • Total Revenue: ₹4,087.75
  • Revenue from Operations: ₹4,072.37
  • Other Income: ₹15.38
  • Total Expenses: ₹3,578.84
  • Cost of Materials Consumed: ₹3,822.03
  • Change in Inventories: (₹452.17) [negative indicates decrease]
  • Employee Benefits Expenses: ₹42.74
  • Finance Cost: ₹39.11
  • Depreciation & Amortization: ₹18.46
  • Other Expenses: ₹108.67
  • Profit Before Tax: ₹508.91
  • Tax Expense: ₹129.79
  • Current Tax: ₹145.58
  • Deferred Tax: (₹15.79) [credit]
  • Net Profit for the Period: ₹379.12
  • Earnings Per Share (Rs. 10 face value):
  • Basic EPS: ₹0.866
  • Diluted EPS: ₹0.862

Half-Yearly Performance (H1 FY27)

  • Total Revenue: ₹8,042.37
  • Net Profit for the Period: ₹749.80
  • Earnings Per Share:
  • Basic EPS: ₹1.726
  • Diluted EPS: ₹1.719

Comparative Figures (Q2 FY26)

  • Total Revenue: ₹3,754.91
  • Net Profit for the Period: ₹258.26
  • Earnings Per Share:
  • Basic EPS: ₹2.395
  • Diluted EPS: ₹1.972

Key Quantitative Figures - Consolidated (Rs. in Lakhs)

Quarterly Performance (Q2 FY27)

  • Total Revenue: ₹10,820.11
  • Revenue from Operations: ₹10,794.28
  • Other Income: ₹25.83
  • Total Expenses: ₹9,286.95
  • Profit Before Tax: ₹1,533.15
  • Tax Expense: ₹556.11
  • Current Tax: ₹500.91
  • Deferred Tax: ₹55.20
  • Net Profit for the Period: ₹977.04
  • Earnings Per Share (Rs. 10 face value):
  • Basic EPS: ₹2.231
  • Diluted EPS: ₹2.221

Half-Yearly Performance (H1 FY27)

  • Total Revenue: ₹20,927.49
  • Net Profit for the Period: ₹1,919.21
  • Earnings Per Share:
  • Basic EPS: ₹4.419
  • Diluted EPS: ₹4.400

Dates of Action

  • Board Meeting Date: November 13, 2026 (commenced at 5:00 PM, concluded at 5:50 PM)
  • Period Ended: September 30, 2026 (Q2 and H1 FY27)
  • Limited Review Report Date: November 13, 2026

Parties Involved

  • Subsidiary: Sriven Pharmachem India Private Limited (wholly-owned material subsidiary)
  • Auditors: Sathuluri & Co., Chartered Accountants (FRN No. 006383S)
  • Stock Exchange: BSE Limited
  • Regulatory Reference: SEBI (LODR) Regulations, 2015 - Regulation 30 and Regulation 33

Capital Structure Impact

  • Paid-up Equity Share Capital (standalone): ₹4,379.89 lakhs (face value ₹10 each) as of September 30, 2026
  • Previous Period Comparison: Paid-up capital was ₹1,077.00 lakhs as of September 30, 2025, and ₹4,223.11 lakhs as of March 31, 2026

Financial Position (Standalone as of September 30, 2026)

  • Total Assets: ₹41,681.70 lakhs
  • Total Equity: ₹33,911.12 lakhs
  • Non-current Assets: ₹29,295.06 lakhs (including investment in Sriven Pharmachem of ₹27,716.95 lakhs)
  • Current Assets: ₹12,386.63 lakhs (including inventories of ₹4,721.37 lakhs and trade receivables of ₹7,278.43 lakhs)
  • Current Liabilities: ₹7,486.42 lakhs (including borrowings of ₹1,375.06 lakhs and trade payables of ₹5,393.41 lakhs)

Cash Flow (Standalone H1 FY27)

  • Net Cash Used in Operating Activities: (₹829.58) lakhs
  • Net Cash Used in Investing Activities: (₹11.77) lakhs
  • Net Cash from Financing Activities: ₹578.52 lakhs
  • Net Decrease in Cash & Equivalents: (₹262.83) lakhs